Tariffs, a biologics boom and the industrialisation crisis in cell and gene therapy are converging to force the most significant rethink of pharmaceutical manufacturing in a generation. For most of […]
- June 17, 2026
- By WM Life Sciences
- Business
Rewinding the Clock: The Science of Cellular Reprogramming Reaches Human Trials
Two biotechs have now cleared the threshold separating longevity science from regulated medicine. This week’s $435 million raise by NewLimit is the latest signal that epigenetic reprogramming is no longer […]
- June 10, 2026
- By WM Life Sciences
- Business
When Your Watch Becomes a Medical Device: The Blurring Boundary Between Consumer Tech and Clinical Care
Smartwatches are detecting heart arrhythmias. Glucose sensors are being worn by people without diabetes. Regulators on both sides of the Atlantic are scrambling to keep pace. The line between wellness […]
- June 3, 2026
- By WM Life Sciences
- Business
Pharma’s Carbon Problem: Ambitious Targets, a Stubborn Reality
The life sciences industry emits more than the aviation sector. With net zero deadlines approaching and regulators tightening disclosure rules, the gap between promise and progress has never been more […]




